NewsBenzingaCharles River Laboratories acquisirà le attività di bioanalisi e DMPK di Frontage Holdings Corporation in Pennsylvania per circa 470 milioni di dollari in contanti, più pagamenti aggiuntivi fino a 75 milioni di dollari Charles River Laboratories acquisirà le attività di bioanalisi e DMPK di Frontage Holdings Corporation in Pennsylvania per circa 470 milioni di dollari in contanti, più pagamenti aggiuntivi fino a 75 milioni di dollari Benzinga 2026.11.09 11:19 (GMT+0) Open on Benzinga Other news Charles River Laboratories To Acquire Frontage Holdings Corporation’s Bioanalysis And DMPK Operations In Pennsylvania For ~$470M In Cash Plus Additional Payments Of Up To $75M HC Wainwright & Co. Assumes United Therapeutics at Buy, Announces Price Target of $660 Safe Harbor CEO Says Company Intends To Evaluate All Available Options, Including Further Reverse Stock Split, To Regain Nasdaq Minimum Bid Price Requirement BTIG Reiterates Buy on Boot Barn Holdings, Maintains $195 Price Target SHF Hldgs Q3 EPS $(0.95) Down From $0.72 YoY, Sales $1.952M Up From $1.834M YoY Greenfire Resources Q3 EPS $(0.11) Down From $(0.09) YoY, Sales $218.134M Up From $102.512M YoY
Charles River Laboratories To Acquire Frontage Holdings Corporation’s Bioanalysis And DMPK Operations In Pennsylvania For ~$470M In Cash Plus Additional Payments Of Up To $75M
Safe Harbor CEO Says Company Intends To Evaluate All Available Options, Including Further Reverse Stock Split, To Regain Nasdaq Minimum Bid Price Requirement
